| TEAD2 with a covalent inhibitor | | homo-2-mer | 217-446 | 1×F3Y; 1×MYR; |
| Assess |
| Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor | | homo-2-mer | 218-446 | 2×MYR; 1×KXH; |
| Assess |
| TEAD2 bound to GNE-7883 | | monomer | 217-446 | 1×TRS; 1×KUR; |
| Assess |
| Crystal structure of TEAD2 bound to Compound 2 | | monomer | 217-446 | 1×QLV; |
| Assess |
| TEAD2 in complex with an inhibitor | | monomer | 217-446 | 1×ZUP; 1×GOL; |
| Assess |
| Crystal Structure of TEAD2 in a covalent complex with TED-662 | | monomer | 217-446 | |
| Assess |
| Crystal structure of hTEAD2 bound to a methoxypyridine lipid pocket binder | | monomer | 217-446 | 1×TRS; 1×Y2S; |
| Assess |
| TEAD2 with a covalent inhibitor | | monomer | 218-446 | 1×MYR; |
| Assess |
| Crystal Structure of TEAD2 in a covalent complex with TED-661 | | monomer | 218-446 | 1×ED0; |
| Assess |
| Crystal structure of human TEAD2-Yap binding domain covalently bound to an allosteric regulator | | monomer | 218-446 | 1×HUY; |
| Assess |
| Crystal Structure of TEAD2 in a covalent complex with TED-642 | | monomer | 218-446 | 1×E8Y; |
| Assess |
| TEAD2 in complex with an inhibitor | | monomer | 220-447 | 1×MYR; |
| Assess |
| TEAD2 in complex with an inhibitor | | monomer | 219-446 | 1×MYR; |
| Assess |
| TEAD2 in complex with an inhibitor | | monomer | 219-446 | 1×MYR; |
| Assess |
| TEAD2 bound to Compound 2 | | monomer | 220-446 | 1×KTF; 1×TRS; |
| Assess |
| TEAD2 bound to Compound 1 | | monomer | 220-446 | 1×KUI; |
| Assess |
| Crystal structure of hTEAD2 in complex with fragment at the interface 2 | | monomer | 221-447 | 1×PLM; |
| Assess |
| Crystal structure of human TEAD2 transcription factor in complex with Flufenamic acid derivative | | monomer | 221-447 | 1×QZ1; |
| Assess |
| Crystal structure of TEAD2 bound to Compound 1 | | monomer | 222-446 | 1×GOL; 1×QSJ; |
| Assess |
| Crystal structure of the palmitoylated human TEAD2 transcription factor | | monomer | 222-446 | |
| Assess |
| Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor | | monomer | 222-446 | 1×MYR; |
| Assess |
| Human Tead2 transcriptional factor | | monomer | 222-446 | |
| Assess |
| Crystal structure of human transcription factor TEAD2 in complex with palmitate | | monomer | 222-446 | 1×PLM; |
| Assess |
| Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor | | monomer | 222-446 | 1×MYR; |
| Assess |
| Crystal structure of human transcription factor TEAD2 in complex with bromo-fenamic acid | | monomer | 222-446 | 1×5E4; |
| Assess |
| Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor | | monomer | 222-446 | 1×MYR; |
| Assess |
| Crystal structure of hTEAD2 in complex with a trisubstituted pyrazole inhibitor | | monomer | 222-446 | 1×MYR; |
| Assess |
| Crystal structure of human transcription factor TEAD2 in complex with flufenamic acid | | monomer | 222-446 | 1×FLF; |
| Assess |
| Crystal structure of TEAD complexed with its inhibitor | | monomer | 222-446 | 1×EY1; |
| Assess |
| Crystal structure of human TEAD2 complexed with its inhibitor TM2. | | monomer | 222-446 | 1×P0I; |
| Assess |
| Crystal Structure of TEAD2 in a covalent complex with TED-664 | | monomer | 222-446 | 1×EGK; |
| Assess |